Why the study?
Does human BNP 32 infusion alter concentrations of other cardiovascular biomarkers in healthy male volunteers?
Does human BNP 32 infusion alter concentrations of other cardiovascular biomarkers in healthy male volunteers?
In healthy volunteers, BNP infusion does not affect plasma concentrations of most other cardiovascular biomarkers, with the exception of decreasing MR-proANP.
BNP shows limited biomarker effects in healthy volunteers; extends mechanistic insights but leaves clinical translation open.
Cardiovascular biomarkers provide independent prognostic information in the assessment of mortality and cardiovascular complications. However, little is known about possible interactions between these biomarkers. In the present study, we evaluated the influence of B-type natriuretic peptide (BNP) on midregional-proadrenomedullin (MR-proADM), C-terminal-proendothelin-1 (CT-proET-1), growth differentiation factor-15 (GDF-15), midregional-proatrial natriuretic peptide (MR-proANP), copeptin, and procalcitonin in healthy volunteers. Ten healthy male subjects (mean age 24 yr) participating in a randomized, placebo-controlled, single-blinded crossover study received placebo or 3.0 pmol·kg(-1)·min(-1) human BNP 32 during a continuous infusion lasting for 4 h. Effects of BNP on other cardiovascular biomarkers were assessed. BNP did not change concentrations of MR-proADM, copeptin, CT-proET1, GDF-15, or procalcitonin. In contrast, MR-proANP was significantly decreased during BNP infusion. BNP as an established cardiovascular biomarker did not affect plasma concentrations of other cardiovascular biomarkers in a model of healthy volunteers.
No takes yet. Share an insight, caveat, or question.
Resl et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: